Browsing Tag
Jiangsu Hengrui Pharmaceuticals
5 posts
Novo Nordisk licenses Hengrui weekly oral GLP-1/GIP drug in deal worth up to $2.6bn
HRS-1596 adds an oral GLP-1/GIP dual agonist to Novo Nordisk’s external pipeline only days after the company licensed technology aimed at monthly and quarterly injections.
Can Kailera become the next major GLP-1 challenger after pricing one of biotech’s biggest IPOs in years?
Kailera Therapeutics priced its IPO at $16 to raise $625M. Read what the deal means for KLRA, obesity drug competition, and biotech funding now.
Are oral GLP-1 pills finally closing the credibility gap with injectables after ribupatide data
Are oral GLP-1 and GIP agonists becoming viable after ribupatide’s Phase 2 data? Explore what this shift means for obesity drug strategy.
GSK to acquire Aiolos Bio to expand respiratory treatment portfolio
GSK plc (LSE/NYSE: GSK) and Aiolos Bio, Inc. (Aiolos) have announced a significant agreement, where GSK will acquire…
Merck strikes €1.4bn deal with Hengrui Pharmaceuticals for next-gen oncology treatments
In a major advancement in cancer treatment, Merck, a frontrunner in science and technology, has declared a strategic…